Delstrigo Tablet, Film Coated
NDC Package 0006-5007-01
Package Information
Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets is dELSTRIGO® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, ORto replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0006-5007 and is authorized under FDA application NDA210807.
Identification & Billing
- RxCUI: 2055813 - doravirine 100 MG / lamiVUDine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
- RxCUI: 2055813 - doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
- RxCUI: 2055813 - DORAVIRINE 100 MG / 3TC 300 MG / Tenofovir disoproxil fumarate 300 MG Oral Tablet
- RxCUI: 2055813 - doravirine 100 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
- RxCUI: 2055815 - Delstrigo 100 MG / 300 MG / 300 MG Oral Tablet
Clinical Specifications
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Non-Nucleoside Analog - [EXT]
- Non-Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleosides - [CS]
Regulatory & Marketing
Hierarchy Structure
- 0006 - Merck Sharp & Dohme Llc
- 0006-5007 - Delstrigo
- 0006-5007-01 - 30 TABLET, FILM COATED in 1 BOTTLE
- 0006-5007 - Delstrigo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0006-5007-01 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Delstrigo, a human prescription drug labeled by Merck Sharp & Dohme Llc. This tablet, film coated is formulated for oral use and contains doravirine; lamivudine; tenofovir disoproxil fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on July 20, 2018. The current certification is valid through December 31, 2027.
How is this Merck Sharp & Dohme Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00006500701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.